Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
FDA: Too Restrictive?
In a debate held on May 8, 2013, major thinkers argued over whether or not the FDA is failing its mandate of protecting the public health, as its approval processes can slow the process of bringing new treatments to market. The debate featured a poll asking participants if they agree with the statement “The FDA’s caution is hazardous to our health.” The results: before the debate, 24% were in favor of that statement, 32% were against it, and 44% were undecided; after the debate, 53% were in favor, 38% were against it, and 9% were undecided. Now, we’re asking GEN readers a similar question.